Longeveron Logo.jpg
Longeveron to Present at Biotech Showcase 2025
December 18, 2024 09:10 ET | Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Longeveron Logo.jpg
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
December 02, 2024 09:05 ET | Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
Wa'el Hashad
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET | Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Longeveron Logo.jpg
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
November 11, 2024 09:05 ET | Longeveron
Longeveron has appointed Devin Blass as Chief Technology Officer (CTO) and SVP of CMC, effective Dec 2, adding capabilities ahead of potential BLA filing.
Longeveron Logo.jpg
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
November 04, 2024 16:05 ET | Longeveron
Longveron will report third quarter 2024 financial results and provide a business update on Tuesday, November 12th after the U.S. financial markets close.
Wa'el Hashad
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
October 14, 2024 09:05 ET | Longeveron
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).
Wa'el Hashad
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
October 09, 2024 09:05 ET | Longeveron
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.
Longeveron Logo.jpg
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
October 07, 2024 09:05 ET | Longeveron
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th
Longeveron Logo.jpg
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 02, 2024 09:05 ET | Longeveron
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Longeveron Logo.jpg
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
September 26, 2024 09:05 ET | Longeveron
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.